Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
23.96
-1.19 (-4.73%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Crescent Biopharma Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
| Market Capitalization | 796 | 232 | - |
| Enterprise Value | 585 | 104 | - |
| Last Close Price | 23.96 | 11.86 | - |
| PS Ratio | 73.42 | 21.38 | - |
| PB Ratio | 4.00 | 1.14 | - |
| P/TBV Ratio | 4.00 | 1.17 | - |
| EV/Sales Ratio | 53.91 | 9.62 | - |
| Debt / Equity Ratio | 0.01 | 0.01 | -3.26 |
| Net Debt / Equity Ratio | -1.04 | -1.04 | -0.24 |
| Net Debt / EBITDA Ratio | 1.39 | 1.39 | - |
| Net Debt / FCF Ratio | 2.92 | 2.92 | -0.11 |
| Asset Turnover | 0.08 | 0.08 | - |
| Quick Ratio | 6.41 | 6.41 | 3.62 |
| Current Ratio | 6.56 | 6.56 | 3.62 |
| Return on Equity (ROE) | -160.75% | -160.75% | - |
| Return on Assets (ROA) | -69.15% | -69.15% | - |
| Return on Capital Employed (ROCE) | -74.70% | -74.70% | -264.40% |
| Earnings Yield | -19.34% | -66.40% | - |
| FCF Yield | -9.10% | -31.25% | - |
| Buyback Yield / Dilution | - | -1465.00% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.